Trends and Innovations from Barcelona (6.20.2025)

Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.

  1. CSA – ARIAA x  9 yrs (4 yr);  ALTO x 6 yrs;  TREAT Earlier x 60 mos.  PALABA 2 yrs 
  2. RA innovation?  RESET RA Vagal Nerve Stimulation
  3. ACR Guidelines 1) Pred  2) MTX  3) removal PPF  4) one and done;  5) reduce but don’t stop
  4. Guidelines – KUDOs EULAR  ILD, RA, Physical Activity, APL, Pt education, lupus nephritis, FMF, antisynthetase syndrome, Class criteria hemochromatosis, PtC Difficult to Rx PsA
  5. D2T-PsA – Grappa  vs EULAR    C2M or D2M          Not D2T-PSA  Refractory PsA
  6. Hemochromatosis  5/11 pts age<50, no DIP,  Iron Fist, MCP234, Hip/ankle surg, JSN, hook osteophyte
  7. New drugs for PsA (deucravacitinib; sonelikumab; icotrokinra IL-23 in PSO)
  8. MAS/HLH -  CD8, IL-18, IFNg (CXCL9) 
  9. Gene therapy in OA knee gene Rx – IL-1RA 3 in development 
  10. TriNetX EMR and JAK-POT caution
  11. RF in EGPA
  12. MTX - does or does not work in PMR
     

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject
×